New stomach acid drug could boost h. pylori cure rates
NCT ID NCT06851468
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study tested whether a new drug called keverprazan, combined with the antibiotic amoxicillin, can effectively treat a first-time H. pylori infection in adults. 264 participants took either keverprazan or esomeprazole (a standard acid reducer) plus amoxicillin for 14 days. Researchers measured how many people were cured and tracked side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Keverprazan (a drug that reduces stomach acid, similar to esomeprazole)
What this could lead to
If successful, keverprazan could offer a new treatment option for first-time H. pylori infections, potentially improving eradication rates.
What could go wrong
This is a completed trial, but results are not yet published. The study is relatively small (264 participants) and only includes first-time infections, so findings may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KeyLabGIDiseasesGansu
Lanzhou, Gansu, 730000, China